Viatris Inc (VTRS): Cash & Equivalents
$1.32B
As of 2025-12-31
$886.50M
As of 2026-06-30
+1.6%
3-year compound annual growth
+9.4%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.32B | +80.0% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $734.80M | -25.9% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $991.90M | -21.3% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $1.26B | +79.7% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $701.20M | -17.0% | 2024-02-28, Balance as of period end |
| 2020-12-31 | $844.40M | +77.5% | 2023-02-27, Balance as of period end |
| 2019-12-31 | $475.60M | +22.5% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $388.10M | n/a | 2021-03-01, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Viatris Inc (VTRS) | 2025-12-31 | $1.32B | +80.0% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $3.12B | +25.3% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $5.08B | +11.3% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $3.56B | +7.8% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $1.31B | +10.8% |
| Organon & Co. (OGN) | 2025-12-31 | $574.00M | -15.0% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $4.55B | +73.1% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $545.00M | +16.5% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
Compare VTRS, REGN, VRTX, TEVA side by side · Screen every company in Pharmaceutical Preparations ↗